Exelixis | EXEL - Current Liabilities


Exelixis reported $370.98M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 305.52M 28.41M Mar/2026
Agios Pharmaceuticals USD 70.22M 11.37M Jun/2026
Akebia Therapeutics USD 173.88M 10.95M Mar/2026
Amgen USD 24.96B 534M Mar/2026
AstraZeneca USD 31.55B 1.02B Jun/2026
Bayer EUR 33.46B 875M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Cytokinetics USD 199.18M 3.27M Mar/2026
Eisai JPY 393.64B 53.39B Jun/2026
Eli Lilly USD 36.63B 1.41B Mar/2026
Exelixis USD 370.98M 34.67M Mar/2026
Genmab DKK 1.43B 686M Dec/2025
Glaxosmithkline GBP 22.43B 6.39B Mar/2026
Incyte USD 1.31B 177.55M Jun/2026
Ionis Pharmaceuticals USD 315.64M 401.36M Jun/2026
MacroGenics USD 95.94M 52.82M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Moderna USD 2.53B 139M Jun/2026
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Neurocrine Biosciences USD 874.5M 42.8M Jun/2026
Novartis USD 31.75B 374M Jun/2026
Pfizer USD 32.65B 1.7B Jun/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Sanofi EUR 30.01B 1.66B Mar/2026
Takeda JPY 2.76T 335.02B Jun/2026
Ultragenyx Pharmaceutical USD 325M 59M Mar/2026
Xencor USD 73.46M 22.45M Mar/2026